# A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

> **NCT07484074** · PHASE1 · COMPLETED · sponsor: **Ollin Biosciences, Inc.** · enrollment: 164 (actual)

## Conditions studied

- Diabetic Macular Edema (DME)
- Neovascular (Wet) Age-Related Macular Degeneration

## Interventions

- **DRUG:** Faricimab
- **DRUG:** OLN324

## Key facts

- **NCT ID:** NCT07484074
- **Lead sponsor:** Ollin Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-12
- **Primary completion:** 2025-10-10
- **Final completion:** 2025-12-09
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484074, "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07484074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*